Actively Recruiting
Randomized, Sham-Controlled Trial of i-Lumen Microcurrent Therapy for Intermediate to Advanced Nonexudative Age-Related Macular Degeneration
Led by i-Lumen Scientific AUS PTY LTD · Updated on 2026-08-26
100
Participants Needed
13
Research Sites
143 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy for patients with intermediate to advanced nonexudative age-related macular degeneration AMD. This clinical device trial aims to better understand how this treatment may impact vision in this condition, using a randomized, sham-controlled, and double-masked study design. Participants will receive either active transpalpebral microcurrent therapy or a sham version as a comparator. They will undergo an initial loading treatment regimen followed by seven maintenance treatments spread over 11 months. After completing treatment, participants will continue monthly visits through Month 14, which is three months after the last therapy session, for evaluation and monitoring. During the trial, participants will be monitored closely with monthly visits to assess changes in best corrected visual acuity BCVA from baseline at Months 3 and 6, among other measures. The study includes careful safety monitoring and aims to identify responders to the therapy. Overall participation spans over a year, including treatment and follow-up periods to evaluate the therapys impact and safety.
CONDITIONS
Brief Title
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
Research Team
M
Meredith Mundy
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here